Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments.

ABSTRACT: Breast cancer (BC) is the most common cancer occurring in women but also rarely develops in men. Recent advances in early diagnosis and development of targeted therapies have greatly improved the survival rate of BC patients. However, the basal-like BC subtype (BLBC), largely overlapping with the triple-negative BC subtype (TNBC), lacks such drug targets and conventional cytotoxic chemotherapies often remain the only treatment option. Thus, the development of resistance to cytotoxic therapies has fatal consequences. To assess the involvement of epigenetic mechanisms and their therapeutic potential increasing cytotoxic drug efficiency, we combined high-throughput RNA- and ChIP-sequencing analyses in BLBC cells. Tumor cells surviving chemotherapy upregulated transcriptional programs of epith

SUBMITTER: Mieczkowska IK 

PROVIDER: S-EPMC8630036 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature